Athena Athena

X
[{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crescendo Biologics Expands its Ongoing Collaboration with Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$790.0 million","upfrontCash":"$40.0 million","newsHeadline":"BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"ANGLE plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Angle PLC, Crescendo Biologics Ink Clinical Services Contract","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crescendo Biologics Secures $32M and Announces Expansion of CB307 Phase 1b Trial in PSMA+ Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Crescendo Biologics Ltd

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The proceeds will fund development of Crescendo's ongoing Phase 1b clinical trial of CB307 (tri-specific humabody) through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort in individuals with PSMA+ metastatic castration-resistant prostate cancer.

            Lead Product(s): CB307,Pembrolizumab

            Therapeutic Area: Oncology Product Name: CB307

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sofinnova Partners

            Deal Size: $32.0 million Upfront Cash: Undisclosed

            Deal Type: Financing July 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Crescendo will use ANGLE's recently launched Portrait Flex assay in its Phase 1 trial investigating the safety and efficacy of CB307, a first-in-class PSMA x CD137 half-life extended bispecific, for treating patients with PSMA positive solid tumours.

            Lead Product(s): CB307

            Therapeutic Area: Oncology Product Name: CB307

            Highest Development Status: Phase I Product Type: Large molecule

            Recipient: ANGLE plc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against cancer and other diseases.

            Lead Product(s): mRNA-based Antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: BioNTech

            Deal Size: $790.0 million Upfront Cash: $40.0 million

            Deal Type: Collaboration January 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The expansion will enable Takeda to access a range of Crescendo’s half-life extension Humabodies for use with its two Humabody programmes, licensed in November 2018 and July 2019.

            Lead Product(s): Humabody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration December 10, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY